These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37876963)

  • 1. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.
    Palmerini E; Frega G; Gambarotti M; Frisoni T; Cesari M; Bazzocchi A; Miceli M; Donati DM; Fanti S; Nanni C; Benini S; Longhi A; Paioli A; Marrari A; Hakim R; Righi A; Ibrahim T
    Front Oncol; 2023; 13():1252359. PubMed ID: 37876963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
    Lanman T; Hayden Gephart M; Bui N; Toland A; Nagpal S
    Case Rep Oncol; 2021; 14(3):1841-1846. PubMed ID: 35111018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy.
    Recine F; De Vita A; Fausti V; Pieri F; Bongiovanni A; Franchini E; Casadei R; Falasconi MC; Oboldi D; Matteucci F; Pallotti MC; Mercatali L; Riva N; Gurrieri L; Vanni S; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
    Front Oncol; 2021; 11():740676. PubMed ID: 35070960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 6. Case report:
    Lazzari C; Pecciarini L; Doglioni C; Pedica F; Gajate AMS; Bulotta A; Gregorc V; Cangi MG
    Front Oncol; 2022; 12():1038774. PubMed ID: 36419889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 8. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report.
    Percy C; Schubert T; Galant C; Kirchgesner T; Mazzeo F
    Clin Case Rep; 2021 Mar; 9(3):1694-1698. PubMed ID: 33768917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development.
    Thein KZ; Myat YM; Park BS; Panigrahi K; Kummar S
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions.
    Gouda MA; Thein KZ; Hong DS
    Cancers (Basel); 2024 Oct; 16(19):. PubMed ID: 39410015
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma.
    Bai C; Zhang L; Wang Y; You X; Ju Y; Sun T; Fan Z
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2933-2937. PubMed ID: 35933643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
    Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
    Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
    Wu WC; Chen MH
    Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
    Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
    Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
    Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
    Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
    Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
    Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.